Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bodycote profits drop 68% as end markets remain 'mixed'

(Sharecast News) - Heat treatment and thermal processing services firm Bodycote delivered a cautious outlook on Friday as it presented its full-year results, with end markets remaining mixed after a "challenging" 2024, in which reported profits dropped sharply due to one-off impairment charges. Adjusted operating profits were up just 1.1% at £129m over the 12 months to 31 December, as an adjusted revenue decline of 5.7% to £757.1m was slightly outweighed by a 120-basis point improvement in the adjusted operating margin to 17.9%.

Statutory operating profits, however, totalled just £37.9m, down 68.2% on 2023, due to £78.3m of previously announced one-off charges.

These comprised a £28.4m impairment charge from the cessation of its ERP tech upgrade, a £31.9m restructuring charge from its Optimise programme, and a £18m goodwill write-down relating to automotive and industrial activities in North America (which the company said carried a high level of associated goodwill from historical acquisitions).

"We delivered a resilient performance in 2024, with our core business growing organically pre-surcharges and good margin improvement despite challenging conditions in many of our end markets," said chief executive Jim Fairbairn.

"This was driven by Specialist Technologies where we saw good growth and strong margin improvement, as well as decisive cost control actions taken in our Automotive and Industrial Precision Heat Treatment businesses."

Looking ahead, the company said that the current run-rate profit performance is at similar levels to the second half, with challenging conditions in automotive and industrial markets combined with strong demand in aerospace and defence.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.